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Severe and fatal viral infections remain common after
HSCT. Adoptive transfer of cytotoxic T lymphocytes
(CTLs) specific for EBV, CMV and Adv antigens can
treat infections that are impervious to conventional
therapies, but extension to additional viruses has been
limited by competition between virus-derived antigens
and laborious manufacturing procedures. We are now
evaluating whether infusion of rapidly-generated donor-
derived pentavalent T cell lines (pCTL), stimulated just
once with peptide libraries spanning immunogenic EBV
(LMP2, EBNA1, BZLF1), Adv (Hexon, Penton), CMV
(pp65, IE1), BK (Large T, VP1) and HHV6 (U90, U11,
U14) antigens, and expanded in the presence of IL4+7
in a G-Rex device, is safe and effective in HSCT recipi-
ents with active infections. With NHLBI-PACT support,
35 clinical-grade pCTL lines have been generated. From
30×106 PBMCs we prepared a mean of 374×106 cells
(range 99-713x106) over 9-11 days. The lines were polyclo-
nal, comprising both CD4+ (57±5%) and CD8+ (35±5%)
cells, with specificity for CMV (IE1: 337±141; pp65:
1059±479 SFC/2x105), EBV (LMP2: 175±87; EBNA1:
116±44; BZLF1: 129±88), Adv (Hexon: 446±153; Penton:
317±108), BK (Large T: 130±67; VP1: 231±104) and
HHV6 (U90: 66±50; U11: 36±18; U14: 82±21) and no
alloreactivity against recipient PHA blasts (mean Cr51
release 1% 20:1 E:T). To date we have infused 10 patients
on study; 4 on DL1 (5×106/m2), 4 on DL2 (1×107/m2)
and 2 on DL3 (2×107/m2), with no adverse events. Three
patients were infused prophylactically (38-43 days post-
HSCT), while 7 received the cells as treatment for one or
more active infections at 59-139 days post-HSCT. Based
on viral load measurements by day 42, the pCTLs were
successful in controlling active CMV (1 complete (CR)
and 1 partial response (PR)), EBV (2 CRs, including a case
of frank PTLD); Adv (1 CR); BK (1 CR, 3 PR) and HHV6
(1 CR) infections. Additionally, 1 patient received cells off
study as treatment for widespread rituximab-resistant
EBV-PTLD. Post-infusion there was an immediate decline
in her EBV viral load with PTLD resolution, coincident
with an increase in circulating EBV-specific T cells. How-
ever, the profound anti-tumor activity mediated by the
rapidly-expanding EBV-directed T cells also produced a
transient systemic inflammatory response syndrome in
this patient, which was controlled with steroids and anti-
TNFR antibody, with no long term adverse effects. In
summary, infusion of pCTLs has thus far proven safe and
is associated with the appearance of virus-reactive T cells
in peripheral blood and subsequent virus clearance.
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